3114-61-2

Basic information

• Product Name: Phenol, 3-methoxy-2-nitro-
• CAS NO: 3114-61-2
• Molecular Formula: C7H7NO4
• Molecular Weight: 169.137
• Mol File: 3114-61-2.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Phenol, 3-methoxy-2-nitro-(CAS DataBase Reference)
• NIST Chemistry Reference: Phenol, 3-methoxy-2-nitro-(3114-61-2)
• EPA Substance Registry System: Phenol, 3-methoxy-2-nitro-(3114-61-2)

Safety Data

• Hazardous Substances Data: 3114-61-2(Hazardous Substances Data)

Upstream product

• 601-89-8 2-nitroresorcinol 
• 77-78-1 dimethyl sulfate 
• 150-19-6 O-methylresorcine 
• 641-49-6 1-fluoro-3-methoxy-2-nitrobenzene 
• 74-88-4 methyl iodide 
• 49698-86-4 3-methoxy-2-nitrophenyl acetate 
• 108-46-3 recorcinol 
• 6665-97-0 1,3-dimethoxy-2-nitrobenzene 
• 107-06-2 1,2-dichloro-ethane 

Downstream Products

• 1026658-72-9 1-[3-(3-Methoxy-2-nitro-phenoxy)-propyl]-5-methyl-4-phenyl-1H-imidazole 
• 849402-65-9 4-methoxy-2-methylbenzoxazole 
• 1160046-61-6 5-((3-methoxy-2-nitrophenoxy)methyl)benzo[d][1,3]dioxole 
• 1160046-57-0 2-((3-methoxy-2-nitrophenoxy)methyl)-1,4-dimethoxy-benzene 
• 1160046-55-8 1-(3-methoxy-2-nitrophenoxy)methyl-4-methoxy-benzene 
• 1160046-59-2 4-((3-methoxy-2-nitrophenoxy)methyl)-1,2-dimethoxy-benzene 
• 40925-69-7 2-amino-3-methoxyphenol 
• 149353-19-5 2-Methoxy-6-[3-(5-methyl-4-phenyl-imidazol-1-yl)-propoxy]-phenylamine 

Relevant articles and documents

THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES

A therapeutic agent for treating at least one disease selected from the group consisting of inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases, comprising: at least one selected from the group consisting of a compound represented by the following general formula (1) and pharmacologically acceptable salts thereof as an active ingredient. [In the formula (1), R1 and R2 may be the same or different and each represents a hydrogen atom, a halogen atom, a hydroxyl group, a carboxy group, a cyano group, an optionally substituted C1-6 alkyl group et al.; R3 represents a hydrogen atom; R4 represents an optionally substituted 4- to 10-membered monocyclic heterocyclic group containing 1 to 4 heteroatoms selected from an oxygen atom, a nitrogen atom, and a sulfur atom; X represents a group represented by the following formula: -CH2-, - CH2-CH2-, -CH2-CH2-CH2-, or -CH2-O-CH2-; and Z represents a hydrogen atom or a hydroxyl group.]

TRIAZOLE AGONISTS OF THE APJ RECEPTOR

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures where the definitions of the variables are provided herein.

Phosphodiesterase inhibitors. Part 3: Design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-dihydropyridazinones with anti-inflammatory and bronchodilatory activity

(-)-6-(7-Methoxy-2-trifluoromethylpyrazolo[1,5-a]pyridin-4-yl)-5-methyl-4, 5-dihydro-3-(2H)-pyridazinone (KCA-1490) is a dual PDE3/4 inhibitor that exhibits potent combined bronchodilatory and anti-inflammatory activity. A survey of potential bicyclic heteroaromatic replacement subunits for the pyrazolo[1,5-a]pyridine core of KCA-1490 has identified the 4-methoxy-2- (trifluoromethyl)benzo[d]thiazol-7-yl and 8-methoxy-2-(trifluoromethyl)quinolin- 5-yl analogues as dual PDE3/4-inhibitory compounds that potently suppress histamine-induced bronchoconstriction and exhibit anti-inflammatory activity in vivo.